Streetbeat News

Regulatory

IVV

Recent inflation data has increased hopes for a Federal Reserve rate cut, positively impacting US stock sentiment. This has led to speculation on whether the S&P 500 and Nasdaq will continue their post-election rally.

Portfolio Pulse from

November 13, 2024 | 3:00 pm

CBSTF

The article discusses the potential impact of the next U.S. president on marijuana stocks, highlighting the Republican party's mixed stance on cannabis reform. This has led to volatile trading in cannabis stocks.

Portfolio Pulse from

November 13, 2024 | 3:00 pm

LAES

SEALSQ Corp (NASDAQ: LAES) aligns with COP29 standards to enhance sustainability in the IoT industry, focusing on carbon crediting frameworks.

Portfolio Pulse from

November 13, 2024 | 2:45 pm

MSFT

OpenAI is set to present its 'blueprint for U.S. AI infrastructure' in Washington, D.C., which includes AI economic zones and government projects funded by private investors. This strategy aims to strengthen U.S. AI capabilities and compete with China.

Portfolio Pulse from

November 13, 2024 | 2:45 pm

META

Meta Platforms is set to face an antitrust trial following a U.S. Federal Trade Commission lawsuit. The lawsuit claims Meta acquired Instagram and WhatsApp to eliminate competition in the social media space.

Portfolio Pulse from

November 13, 2024 | 2:45 pm

SMCI

Super Micro's stock is experiencing a decline due to delays in filing its quarterly and past annual reports. The company also requires more time to appoint a new auditor.

Portfolio Pulse from

November 13, 2024 | 2:30 pm

LEXX

Lexaria Bioscience Corp. has received ethics board approval for its 12-week Phase 1b DehydraTECH GLP-1 study focused on diabetes and weight loss. The manufacturing of clinical test articles for the study has been completed.

Portfolio Pulse from

November 13, 2024 | 2:30 pm

ATAI

atai Life Sciences received FDA approval for its investigational new drug application for VLS-01, a buccal film formulation of DMT, advancing its therapeutic pipeline in Q3 2024.

Portfolio Pulse from

November 13, 2024 | 2:30 pm

JNJ

Johnson & Johnson is outperforming the industry with strong growth in its oncology franchise. Darzalex sales increased by 20.7% in Q3 2024, and the company is seeking regulatory approval for Darzalex Faspro.

Portfolio Pulse from

November 13, 2024 | 2:30 pm

HSCS

HeartSciences' AI-ECG technology has been approved for CMS Medicare and Medicaid reimbursement, allowing outpatient settings to receive payments for their MyoVista® algorithms upon FDA clearance.

Portfolio Pulse from

November 13, 2024 | 2:15 pm